Incyte Corporation · NASDAQ:INCY
Incyte — Merger or Acquisition (April 2024)
14 slides from Incyte's merger presentation, Apr 23, 2024
Slide 1: Incyte to Acquire Escient Pharmaceuticals
Incyte to Acquire Escient Pharmaceuticals April 23, 2024
Slide 2: Agenda
Agenda Ben Strain Introduction Head of Investor Relations Hervé Hoppenot Acquisition Overview Chief Executive Officer Pablo Cagnoni EP262 / EP547 Review President, Head of Research & Development Christiana Stamoulis Chief Financial Officer Steven Stein Available for Q&A Chief Medical Officer Jim Lee
Slide 3: Forward Looking Statements
Forward Looking Statements Except for the historical information set forth herein, the matters set forth in this presentation, including statements regarding the opportunities presented by this transaction, whether and when EP262 or EP547 will be approved for use; whether and when Incyte will bring
Slide 4: Incyte to Acquire Escient Pharmaceuticals
Incyte to Acquire Escient Pharmaceuticals Hervé Hoppenot, Chief Executive Officer
Slide 5: Acquisition of Escient Pharmaceuticals Enhances Portfolio with Potential to Diversify Future Revenue
Acquisition of Escient Pharmaceuticals Enhances Portfolio with Potential to Diversify Future Revenue Adds two first-in-class clinical stage IAI assets Complements internal pipeline Leverages development and commercial capabilities ™ Large potential commercial opportunity in multiple indications Seve
Slide 6: Significant Growth Potential for IAI Franchise
Significant Growth Potential for IAI Franchise Financial Overview Transaction Details Transaction Details Financial Impact Financial impact ▪ $750 million all-cash ▪ Limited impact on 2024 R&D expenses ▪ Closing expected by 3Q 2024; subject to ▪ Significant synergies expected, including utilization
Slide 7: EP262 / EP547 Review
EP262 / EP547 Review Pablo Cagnoni, President, Head of Research & Development
Slide 8: MRGPRX2 Provides Novel and Targeted Approach for Multiple Indications
MRGPRX2 Provides Novel and Targeted Approach for Multiple Indications Lead Program EP262 ▪ Potent and highly-selective antagonist that blocks the activation of Mas-related G protein-coupled receptor X2 (MRGPRX2) ▪ Blocks mast cell activation, independent of IgE ▪ Oral, once-daily, small molecule inh
Slide 9: MRGPRX4 Provides Novel and Targeted Approach for Cholestatic Pruritus
MRGPRX4 Provides Novel and Targeted Approach for Cholestatic Pruritus EP547 ▪ Potent and highly-selective antagonist that blocks the activation of Mas-related G protein-coupled receptor X4 (MRGPRX4) ▪ Expressed almost exclusively on sensory neurons in the dorsal root ganglia ▪ Activated by bile acid
Slide 10: Phase 1 Data Demonstrates Clean Safety Profile
Phase 1 Data Demonstrates Clean Safety Profile EP262 1 EP547 2 ▪ SAD/MAD study in healthy volunteers ▪ SAD/MAD study in healthy volunteers and patients with chronic cholestatic or kidney ▪ Wide dose/exposure range evaluated disease ▪ Safe and well-tolerated ▪ Wide dose/exposure range evaluated ▪ No
Slide 11: Large Patient Populations with Unmet Need in Initial Indications with EP262
Large Patient Populations with Unmet Need in Initial Indications with EP262 Chronic Spontaneous Chronic Inducible Urticaria Urticaria U.S. Prevalence: 1 - 2 million+ 500k - 1 million 2nd generation H1 2nd generation H1 1st Line Therapy: antihistamines antihistamines Unmet Need: 30-50% of patients no
Slide 12: MRGPRX Programs Development Timeline
MRGPRX Programs Development Timeline Product Indication Status 2024 2025 2026 2027 2028 2029 2030+ CIndU Phase 1b PoC Dermatology/IAI EP262 CSU Phase 2 PoC (MRGPRx2) AD Phase 2a PoC EP547 CP Phase 2a PoC (MRGPRx4) Phase 2 Phase 3 Potential U.S. Approval CIndU= chronic inducible urticaria; CSU= chron
Slide 13: Q&A
Q&A
Slide 14: Solve On
Solve On